| Audit Review Table | | | | | |
|---|--------------------------|-------------------------|------------------------------|---------------|--|
| Blue Cross and Blue Shield of New Mexico (Org ID: 1825, | SubID: 9522, Medicaid, | Spec Area: Non | e, Spec Proj: None, Contract | Number: None) | |
| Measurement Year - 2016; Date & Timestamp - 6/9/2017 3: | 14:06 PM | - | | | |
| The | Auditor lock has been ap | pplied to this subr | nission. | | |
| Measure/Data Element | Benefit Offered | Rate | Audit Designation | Comment | |
| Effectiveness of Care: Prevention and | | | | | |
| Screening | | | | | |
| Adult BMI Assessment (aba) | | 76.16% | R | Reportable | |
| Weight Assessment and Counseling for Nutrition and | | | | | |
| Physical Activity for Children/Adolescents | | | | | |
| (wcc) | | | | | |
| BMI Percentile | | E0 7 00/ | | Depertokla | |
| | | <u>58.76%</u> 49.00% | R | Reportable | |
| Counseling for Nutrition | | | R | Reportable | |
| Counseling for Physical Activity | | 45.01% | R | Reportable | |
| Childhood Immunization Status (cis) | | 70.4004 | | | |
| DTaP | | 76.16% | R | Reportable | |
| IPV | | 88.30% | R | Reportable | |
| MMR | | 87.20% | R | Reportable | |
| HiB | | 87.42% | R | Reportable | |
| Hepatitis B | | 88.30% | R | Reportable | |
| VZV | | 87.42% | R | Reportable | |
| Pneumococcal Conjugate | | 75.72% | R | Reportable | |
| Hepatitis A | | 87.20% | R | Reportable | |
| Rotavirus | | 75.28% | R | Reportable | |
| Influenza | | 42.60% | R | Reportable | |
| Combination #2 | | 72.85% | R | Reportable | |
| Combination #3 | | 70.20% | R | Reportable | |
| Combination #4 | | 69.76% | R | Reportable | |
| Combination #5 | | 62.03% | R | Reportable | |
| Combination #6 | | 37.31% | R | Reportable | |
| Combination #7 | | 61.81% | R | Reportable | |
| Combination #8 | | 36.87% | R | Reportable | |
| Combination #9 | | 34.44% | R | Reportable | |
| Combination #10 | | 34.22% | R | Reportable | |
| mmunizations for Adolescents (ima) | | | | | |

| | | | _ | |
|---|---|--------|---|------------|
| Meningococcal | | 66.00% | R | Reportable |
| Tdap | | 82.34% | R | Reportable |
| HPV | | 19.21% | R | Reportable |
| Combination #1 | | 65.12% | R | Reportable |
| Combination #2 | | 18.32% | R | Reportable |
| Lead Screening in Children (Isc) | | 33.49% | R | Reportable |
| Breast Cancer Screening (bcs) | | 41.65% | R | Reportable |
| Cervical Cancer Screening (ccs) | | 52.55% | R | Reportable |
| Chlamydia Screening in Women (chl) | | | | |
| 16-20 Years | | 42.37% | R | Reportable |
| 21-24 Years | | 50.83% | R | Reportable |
| Total | | 47.35% | R | Reportable |
| Effectiveness of Care: Respiratory | | | | · · · · · |
| Appropriate Testing for Children with Pharyngitis (cwp) | Y | 63.78% | R | Reportable |
| Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr) | | 27.92% | R | Reportable |
| Pharmacotherapy Management of COPD Exacerbation (pce) | Y | | | |
| Systemic Corticosteroid | | 36.87% | R | Reportable |
| Bronchodilator | | 45.54% | R | Reportable |
| Medication Management for People With Asthma (mma) | Y | | | |
| 5-11 Years: Medication Compliance 50% | | 52.28% | R | Reportable |
| 5-11 Years: Medication Compliance 75% | | 22.80% | R | Reportable |
| 12-18 Years: Medication Compliance 50% | | 39.90% | R | Reportable |
| 12-18 Years: Medication Compliance 75% | | 20.19% | R | Reportable |
| 19-50 Years: Medication Compliance 50% | | 58.76% | R | Reportable |
| 19-50 Years: Medication Compliance 75% | | 33.20% | R | Reportable |
| 51-64 Years: Medication Compliance 50% | | 72.45% | R | Reportable |
| 51-64 Years: Medication Compliance 75% | | 40.82% | R | Reportable |
| Total: Medication Compliance 50% | | 55.99% | R | Reportable |
| Total: Medication Compliance 75% | | 29.39% | R | Reportable |
| Asthma Medication Ratio (amr) | Y | | | • |
| 5-11 Years | | 74.57% | R | Reportable |

| 1/2-10 Fears 0.1.43% R Reportable 19-50 Years 48.55% R Reportable 51-64 Years 55.80% R Reportable Total 58.04% R Reportable Effectiveness of Carci Cardiovascular Controlling High Blood Pressure (cbp) 55.60% R Reportable Presistence of Beta-Blocker Treatment After a Heart Y Statin After Treatment After a Heart Y Statin After Therapy: 21-75 Years (Male) Second Statin Therapy: 40-75 Years (Female) Second Statin Therapy: 40-75 Years (Female) Second Statin Therapy: 40-75 Years (Female) Second Statin Therapy: 70al Comprehensive Diabetes Care (cdc) Received Statin Therapy: 70al Second Statin Atherence 80%: 70al Second Statin Therapy: 70al Second Statin Atherence 80%: 70al Comprehensive Diabetes Care (cdc) Memory of Care (cdc) | 40.40.Veere | | 04.049/ | | Devestable |
|---|---|---|---------|----------|--------------|
| 51-64 Years 55.80% R Reportable Total Total 68.04% R Reportable Effectiveness of Care: Cardiovascular Keportable Reportable Reportable Persistence of Beta-Blocker Treatment After a Heart Attack (pbh) Y 63.88% R Reportable Statin Therapy for Patients With Cardiovascular Disease (spc) Y 63.88% R Reportable Received Statin Therapy: 21-75 Years (Male) 56.65% R Reportable Statin Adherence 80%: 21-75 Years (Male) 60.56% R Reportable Statin Adherence 80%: 20-75 Years (Female) 39.64% R Reportable Statin Adherence 80%: 70-75 Years (Female) 56.85% R Reportable Comprehensive Diabetes Statin Adherence 80%: Total 59.47% R Reportable Comprehensive Diabetes Comprehensive Diabetes Comprehensive Diabetes R Reportable Comprehensive Diabetes Control (>9.0%) 48.57% R Reportable Medical Attention for Nephropathy 87.42% R Reportable Medical Attention for Nephropathy 87.42% R Reportable Medical Attention for Nephropathy 87.42% R Reportable Medical Attention for Nephro | 12-18 Years | | 61.34% | R | Reportable |
| Total 58.04% R Reportable Effectiveness of Care: Cardiovascular Controlling High Blood Pressure (cbp) 55.60% R Reportable Persistence of Beta-Blocker Treatment After a Heart Attack (pbh) Y 63.86% R Reportable Statin Therapy: 21-75 Years (Male) 56.65% R Reportable Beceived Statin Therapy: 21-75 Years (Male) 60.56% R Reportable Statin Adherence 80%: 21-75 Years (Male) 60.56% R Reportable Statin Adherence 80%: 21-75 Years (Female) 38.64% R Reportable Statin Adherence 80%: 72-75 Years (Female) 56.82% R Reportable Statin Adherence 80%: 75 Years (Female) 56.82% R Reportable Beceived Statin Therapy: 70-75 Years (Female) 56.82% R Reportable Statin Adherence 80%: 70-75 Years (Female) 56.82% R Reportable Beceived Statin Therapy: 70-75 Years (Female) 56.82% R Reportable Beceived Statin Adherence 80%: 70-tal 50.33% R Reportable Betain Adherence 80%: 70-tal 50.47% R Reportable Comprehensive Diabetes Care (dcd) Menoglobin A1c (HbA1c) Testing NR NR NR HbA1c Control (<8.0%) | | | | | 1 |
| Effectiveness of Care: Cardiovascular 55.60% R Reportable Controlling High Blood Pressure (cbp) 55.60% R Reportable Persistence of Beta-Blocker Treatment After a Heart Attack (pbh) Y 63.86% R Reportable Statin Therapy for Patients With Cardiovascular Disease (spc) Y 60.66% R Reportable Received Statin Therapy: 21-75 Years (Male) 66.66% R Reportable Statin Adherence 80%: 21-75 Years (Male) 60.66% R Reportable Received Statin Therapy: 40-75 Years (Female) 39.64% R Reportable Statin Adherence 80%: 40-75 Years (Female) 56.82% R Reportable Statin Adherence 80%: 40-75 Years (Female) 59.47% R Reportable Statin Adherence 80%: 40-75 Years (Female) 59.47% R Reportable Comprehensive Diabetes Care (cd) 59.47% R Reportable Comprehensive Diabetes Care (cd) 41.94% R Reportable HbA1c Control (<50.0%) | | | | | |
| Controlling High Blood Pressure (cbp) 55.60% R Reportable Persistence of Beta-Blocker Treatment After a Heart Attack (pbh) Y 63.86% R Reportable Statin Therapy for Patients With Cardiovascular Disease (spc) Y 63.86% R Reportable Received Statin Therapy: 21-75 Years (Male) 56.65% R Reportable Statin Adherence 80%: 21-75 Years (Male) 60.65% R Reportable Received Statin Therapy: 20-75 Years (Male) 56.68% R Reportable Statin Adherence 80%: 21-75 Years (Female) 56.82% R Reportable Statin Adherence 80%: 40-75 Years (Female) 56.82% R Reportable Statin Adherence 80%: 70tal 50.33% R Reportable Effectiveness of Care: Diabetes 50.47% R Reportable Comprehensive Diabetes Care (cdc) 19.47% R Reportable HbA1c Control (<50.0%) | | | 58.04% | R | Reportable |
| Persistence of Beta-Blocker Treatment After a Heart Attack (pbh) Y 63.86% R Reportable Stain Therapy for Patients With Cardiovascular Disease (spc) Y Received Stain Therapy: 21-75 Years (Male) 56.65% R Reportable Stain Adherence 80%: 21-75 Years (Male) 60.56% R Reportable Stain Adherence 80%: 21-75 Years (Female) 39.64% R Reportable Stain Adherence 80%: 40-75 Years (Female) 39.64% R Reportable Stain Adherence 80%: 40-75 Years (Female) 50.63% R Reportable Stain Adherence 80%: 40-75 Years (Female) 50.43% R Reportable Comprehensive Diabetes Care (cdc) Comprehensive Diabetes Care (cdc) Hand Control (<8.0%) | | | | | |
| Attack (pbh)Y63.86%RReportableStatin Therapy for Patients With Cardiovascular Disease (spc)YReceived Statin Therapy: 21-75 Years (Male)56.65%RReportableStatin Adherence 80%: 21-75 Years (Male)60.66%RReportableStatin Adherence 80%: 40-75 Years (Female)39.64%RReportableStatin Adherence 80%: 40-75 Years (Female)56.82%RReportableStatin Adherence 80%: 40-75 Years (Female)56.82%RReportableStatin Adherence 80%: 40-75 Years (Female)56.82%RReportableComprehensive Diabetes59.47%RReportableEffectiveness of Care: Diabetes82.56%RReportableComprehensive Diabetes Care (cdc)82.56%RReportableHbh 1c Poor Control (>9.0%)48.57%RReportableHbh 1c Poor Control (>9.0%)44.57%RReportableHbh 1c Control (<7.0%) | | | 55.60% | R | Reportable |
| Attack (pbh) Y Attack (pbh) Statin Therapy for Patients With Cardiovascular Disease (spc) Y X Received Statin Therapy: 21-75 Years (Male) 56.65% R Reportable Statin Adherence 80%: 21-75 Years (Male) 60.56% R Reportable Received Statin Therapy: 40-75 Years (Female) 39.64% R Reportable Statin Adherence 80%: 40-75 Years (Female) 56.82% R Reportable Statin Adherence 80%: 40-75 Years (Female) 56.82% R Reportable Statin Adherence 80%: 40-75 Years (Female) 56.82% R Reportable Statin Adherence 80%: 40-75 Years (Female) 59.47% R Reportable Statin Adherence 80%: 40-75 Years (Female) 59.47% R Reportable Effectiveness of Care: Diabetes Total 59.47% R Reportable Comprehensive Diabetes Care (cdc) 48.57% R Reportable HbA1c Poor Control (>9.0%) 49.57% R Reportable HbA1c Control (<7.0%) | | Y | 63,86% | R | Reportable |
| Disease (spc)YCRReportableReceived Statin Therapy: 21-75 Years (Male)60.56%RRReportableStatin Adherence 80%: 21-75 Years (Female)39.64%RReportableReceived Statin Therapy: 40-75 Years (Female)56.82%RReportableStatin Adherence 80%: 40-75 Years (Female)50.33%RReportableStatin Adherence 80%: Total50.33%RReportableStatin Adherence 80%: Total59.47%RReportableEffectiveness of Care: Diabetes59.47%RReportableComprehensive Diabetes Care (cdc)82.56%RReportableHemoglobin Atc (HbA1c) Testing82.56%RReportableHbA1c Control (<8.0%) | | • | 00.0070 | | |
| Received Statin Therapy: 21-75 Years (Male)56.65%RReportableStatin Adherence 80%: 21-75 Years (Male)60.56%RReportableReceived Statin Therapy: 40-75 Years (Female)39.64%RReportableStatin Adherence 80%: 40-75 Years (Female)56.82%RReportableStatin Adherence 80%: 10-75 Years (Female)56.82%RReportableStatin Adherence 80%: 10-1350.33%RReportableComprehensive Diabetes Care (Cd)59.47%RReportableHemoglobin A1c (HbA1c) Testing82.56%RReportableHah 1c Control (<8.0%) | | Y | | | |
| Statin Adherence 80%: 21-75 Years (Male)60.56%RReportableReceived Statin Therapy: 40-75 Years (Female)39.64%RReportableStatin Adherence 80%: 40-75 Years (Female)56.82%RReportableStatin Adherence 80%: Total50.33%RReportableStatin Adherence 80%: Total59.47%RReportableEffectiveness of Care: Diabetes50.33%RReportableComprehensive Diabetes Care (cdc)111Hemoglobin Atc (HbA1c) Testing82.56%RReportableHbA1c Poor Control (>9.0%)48.57%RReportableHbA1c Control (<20.0%) | | • | | | |
| Received Statin Therapy: 40-75 Years (Female) 39.64% R Reportable Statin Adherence 80%: 40-75 Years (Female) 56.82% R Reportable Received Statin Therapy: Total 50.33% R Reportable Statin Adherence 80%: Total 59.47% R Reportable Effectiveness of Care: Diabetes 59.47% R Reportable Comprehensive Diabetes Care (cdc) 82.56% R Reportable Hemoglobin A1c (HbA1c) Testing 82.56% R Reportable HbA1c Control (<8.0%) | | | | | |
| Statin Adherence 80%: 40-75 Years (Female)56.82%RReportableReceived Statin Therapy: Total50.33%RReportableStatin Adherence 80%: Total59.47%RReportableComprehensive DiabetesComprehensive Diabetes Care (cdc)Hemoglobin A1c (HbA1c) Testing82.56%RReportableHbA1c Poor Control (>9.0%)48.57%RReportableHbA1c Control (<8.0%) | | | | | Reportable |
| Received Statin Therapy: Total 50.33% R Reportable Statin Adherence 80%: Total 59.47% R Reportable Effectiveness of Care: Diabetes | | | | R | Reportable |
| Statin Adherence 80%: Total 59.47% R Reportable Effectiveness of Care: Diabetes 6000000000000000000000000000000000000 | Statin Adherence 80%: 40-75 Years (Female) | | 56.82% | R | Reportable |
| Effectiveness of Care: Diabetes Comprehensive Diabetes Care (cdc) Hemoglobin A1c (HbA1c) Testing 82.56% R Reportable HbA1c Poor Control (>9.0%) 48.57% R Reportable HbA1c Control (<8.0%) | Received Statin Therapy: Total | | 50.33% | R | Reportable |
| Comprehensive Diabetes Care (cdc)Image: control (second)ReportableHemoglobin A1c (HbA1c) Testing82.56%RReportableHbA1c Poor Control (second)48.57%RReportableHbA1c Control (second)41.94%RReportableHbA1c Control (second)41.94%RReportableHbA1c Control (second)51.21%RReportableBlood Pressure Control (second)55.41%RReportableStatin Therapy for Patients With Diabetes (spd)YImage: control (second)Image: control (second)Received Statin Therapy40.68%RReportableEffectiveness of Care: MusculoskeletalY62.31%RReportableEffectiveness of Care: BehavioralYImage: control (second)YImage: control (second)Antidepressant Medication Management (amm)YStatin SecondRReportableEffective Acute Phase TreatmentS0.56%RReportable | Statin Adherence 80%: Total | | 59.47% | R | Reportable |
| Hemoglobin A1c (HbA1c) Testing82.56%RReportableHbA1c Poor Control (>9.0%)48.57%RReportableHbA1c Control (<8.0%) | Effectiveness of Care: Diabetes | | | | |
| HbA1c Poor Control (>9.0%)48.57%RReportableHbA1c Control (<8.0%) | Comprehensive Diabetes Care (cdc) | | | | |
| HbA1c Control (<8.0%)41.94%RReportableHbA1c Control (<7.0%) | Hemoglobin A1c (HbA1c) Testing | | 82.56% | R | Reportable |
| HbA1c Control (<7.0%)NRNot ReportedEye Exam (Retinal) Performed51.21%RReportableMedical Attention for Nephropathy87.42%RReportableBlood Pressure Control (<140/90 mm Hg) | HbA1c Poor Control (>9.0%) | | 48.57% | R | Reportable |
| Eye Exam (Retinal) Performed51.21%RReportableMedical Attention for Nephropathy87.42%RReportableBlood Pressure Control (<140/90 mm Hg) | HbA1c Control (<8.0%) | | 41.94% | R | Reportable |
| Medical Attention for Nephropathy87.42%RReportableBlood Pressure Control (<140/90 mm Hg) | HbA1c Control (<7.0%) | | | NR | Not Reported |
| Blood Pressure Control (<140/90 mm Hg)55.41%RReportableStatin Therapy for Patients With Diabetes (spd)Y40.68%RReportableReceived Statin Therapy40.68%RReportableStatin Adherence 80%51.56%RReportableEffectiveness of Care: MusculoskeletalY62.31%RReportableDisease-Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)Y62.31%RReportableEffectiveness of Care: BehavioralY62.31%RReportableAntidepressant Medication Management (amm)YMCCEffective Acute Phase Treatment50.56%RReportable | Eye Exam (Retinal) Performed | | 51.21% | R | Reportable |
| Statin Therapy for Patients With Diabetes (spd) Y Image: Constraint of the co | Medical Attention for Nephropathy | | 87.42% | R | Reportable |
| Statin Therapy for Patients With Diabetes (spd) Y Image: Constraint of the co | Blood Pressure Control (<140/90 mm Hg) | | 55.41% | R | Reportable |
| Received Statin Therapy40.68%RReportableStatin Adherence 80%51.56%RReportableEffectiveness of Care: MusculoskeletalY62.31%RReportableDisease-Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)Y62.31%RReportableEffectiveness of Care: BehavioralY62.31%RReportableAntidepressant Medication Management (amm)YEffective Acute Phase Treatment50.56%RReportable | Statin Therapy for Patients With Diabetes (spd) | Y | | | · |
| Statin Adherence 80% 51.56% R Reportable Effectiveness of Care: Musculoskeletal V 62.31% R Reportable Disease-Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art) Y 62.31% R Reportable Effectiveness of Care: Behavioral Y 62.31% R Reportable Antidepressant Medication Management (amm) Y V R Reportable Effective Acute Phase Treatment 50.56% R Reportable | | | 40.68% | R | Reportable |
| Effectiveness of Care: Musculoskeletal Disease-Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art) Y 62.31% R Reportable Effectiveness of Care: Behavioral Y 62.31% R Reportable Antidepressant Medication Management (amm) Y Image: Colspan="4">Colspan="4"Colspan="4">Colspan="4"Colspan= | Statin Adherence 80% | | 51.56% | R | • |
| Disease-Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)Y62.31%RReportableEffectiveness of Care: BehavioralAntidepressant Medication Management (amm)YEffective Acute Phase Treatment50.56%RReportable | Effectiveness of Care: Musculoskeletal | | | <u> </u> | • |
| Rheumatoid Arthritis (art) Y 62.31% R Reportable Effectiveness of Care: Behavioral Antidepressant Medication Management (amm) Y Image: Constraint of the section of the se | | | | | 5 |
| Effectiveness of Care: Behavioral Antidepressant Medication Management (amm) Y Effective Acute Phase Treatment 50.56% R Reportable | | Y | 62.31% | R | Reportable |
| Antidepressant Medication Management (amm) Y Image: Constraint of the sector of the s | | | | | |
| Effective Acute Phase Treatment 50.56% R Reportable | | Y | | | |
| | | | 50.56% | R | Reportable |
| | | | | | |

| Follow-Up Care for Children Prescribed ADHD Medication (add) | Y | | | |
|---|---|--------|----|-------------------|
| Initiation Phase | | 51.16% | R | Reportable |
| Continuation and Maintenance (C&M) Phase | | 70.21% | R | Reportable |
| Follow-Up After Hospitalization for Mental Illness (fuh) | Y | | | |
| 30-Day Follow-Up | | 58.27% | R | Reportable |
| 7-Day Follow-Up | | 37.21% | R | Reportable |
| Follow-Up After Emergency Department Visit for Mental Illness (fum) | Y | | | |
| 30-Day Follow-Up | | 56.38% | R | Reportable |
| 7-Day Follow-Up | | 45.16% | R | Reportable |
| Follow-Up After Emergency Department Visit for Alcohol and Other Drug Dependence (fua) | Y | | | |
| 30-Day Follow-Up: 13-17 Years | | 13.33% | R | Reportable |
| 7-Day Follow-Up: 13-17 Years | | 4.44% | R | Reportable |
| 30-Day Follow-Up: 18+ Years | | 17.78% | R | Reportable |
| 7-Day Follow-Up: 18+ Years | | 11.16% | R | Reportable |
| 30-Day Follow-Up: Total | | 17.69% | R | Reportable |
| 7-Day Follow-Up: Total | | 11.04% | R | Reportable |
| Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd) | Y | 78.02% | R | Reportable |
| Diabetes Monitoring for People With Diabetes and Schizophrenia (smd) | | 46.00% | R | Reportable |
| Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc) | | 50.00% | NA | Small Denominator |
| Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa) | Y | 47.81% | R | Reportable |
| Metabolic Monitoring for Children and Adolescents on Antipsychotics (apm) | Y | | | |
| 1-5 Years | | 40.00% | NA | Small Denominator |

| 6-11 Years | | 28.57% | R | Reportable |
|--|----|---------|----|-------------------|
| | | | R | • |
| 12-17 Years | | 31.86% | | Reportable |
| Total | | 30.84% | R | Reportable |
| Effectiveness of Care: Medication | | | | |
| Annual Monitoring for Patients on Persistent | Y | | | |
| Medications (mpm) | | 00.000/ | | Danastakla |
| ACE Inhibitors or ARBs | | 83.30% | R | Reportable |
| Digoxin | | 52.17% | NA | Small Denominator |
| Diuretics | | 84.70% | R | Reportable |
| Total | | 83.70% | R | Reportable |
| Effectiveness of Care: | | | | |
| Non-Recommended Cervical Cancer Screening in | | 4.570/ | | |
| Adolescent | | 1.57% | R | Reportable |
| Females (ncs) | Y | 88.26% | R | Depertable |
| Appropriate Treatment for Children With URI (uri) | ř | 88.20% | ĸ | Reportable |
| Avoidance of Antibiotic Treatment in Adults with Acute | Y | 28.51% | R | Reportable |
| Bronchitis (aab) | Į. | 20.0170 | | Reportable |
| Use of Imaging Studies for Low Back Pain (Ibp) | | 70.15% | R | Reportable |
| Use of Multiple Concurrent Antipsychotics in Children | | | | |
| and | Y | | | |
| Adolescents (apc) | | | | |
| 1-5 Years | | 0.00% | NA | Small Denominator |
| 6-11 Years | | 3.53% | R | Reportable |
| 12-17 Years | | 4.11% | R | Reportable |
| Total | | 3.81% | R | Reportable |
| Access/Availability of Care | | | | |
| Adults' Access to Preventive/Ambulatory Health | | | | |
| Services (aap) | | | | |
| 20-44 Years | | 68.39% | R | Reportable |
| 45-64 Years | | 79.13% | R | Reportable |
| 65+ Years | | 89.34% | R | Reportable |
| Total | | 73.10% | R | Reportable |
| Children and Adolescents' Access to Primary Care | | | | |
| Practitioners (cap) | | | | |
| 12-24 Months | | 93.25% | R | Reportable |
| 25 Months - 6 Years | | 82.02% | R | Reportable |

| 7-11 Years | | 84.82% | R | Reportable |
|---|---|--------|----|-------------------|
| 12-19 Years | | 83.89% | R | Reportable |
| Annual Dental Visit (adv) | Y | | | • |
| 2-3 Years | | 51.12% | R | Reportable |
| 4-6 Years | | 67.17% | R | Reportable |
| 7-10 Years | | 70.71% | R | Reportable |
| 11-14 Years | | 66.84% | R | Reportable |
| 15-18 Years | | 56.43% | R | Reportable |
| 19-20 Years | | 37.77% | R | Reportable |
| Total | | 61.78% | R | Reportable |
| Initiation and Engagement of AOD Dependence Treatment (iet) | Y | | | |
| Initiation of AOD Treatment: 13-17 Years | | 36.72% | R | Reportable |
| Engagement of AOD Treatment: 13-17 Years | | 7.91% | R | Reportable |
| Initiation of AOD Treatment: 18+ Years | | 36.26% | R | Reportable |
| Engagement of AOD Treatment: 18+ Years | | 14.56% | R | Reportable |
| Initiation of AOD Treatment: Total | | 36.27% | R | Reportable |
| Engagement of AOD Treatment: Total | | 14.39% | R | Reportable |
| Prenatal and Postpartum Care (ppc) | | | | |
| Timeliness of Prenatal Care | | 75.50% | R | Reportable |
| Postpartum Care | | 58.06% | R | Reportable |
| Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (app) | Y | | | |
| 1-5 Years | | 33.33% | NA | Small Denominator |
| 6-11 Years | | 60.98% | R | Reportable |
| 12-17 Years | | 57.81% | R | Reportable |
| Total | | 58.33% | R | Reportable |
| Utilization | | | | |
| Frequency of Ongoing Prenatal Care (fpc) | | | | |
| <21 Percent | | 11.70% | R | Reportable |
| 21-40 Percent | | 8.61% | R | Reportable |
| 41-60 Percent | | 9.93% | R | Reportable |
| 61-80 Percent | | 13.91% | R | Reportable |
| 81+ Percent | | 55.85% | R | Reportable |
| Well-Child Visits in the First 15 Months of Life (w15) | | | | |
| 0 Visits | | 3.99% | R | Reportable |

| 1 Visit | | 2.44% | R | Reportable |
|--|---|--------|----|--------------|
| 2 Visits | | 3.57% | R | Reportable |
| 3 Visits | | 5.61% | R | Reportable |
| 4 Visits | | 9.97% | R | Reportable |
| 5 Visits | | 16.07% | R | Reportable |
| 6+ Visits | | 58.35% | R | Reportable |
| Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34) | | 55.84% | R | Reportable |
| Adolescent Well-Care Visits (awc) | | 32.25% | R | Reportable |
| Frequency of Selected Procedures (fsp) | | | R | Reportable |
| Ambulatory Care: Total (amba) | | | R | Reportable |
| Ambulatory Care: Dual Eligibles (ambb) | | | NR | Not Reported |
| Ambulatory Care: Disabled (ambc) | | | NR | Not Reported |
| Ambulatory Care: Other (ambd) | | | NR | Not Reported |
| Inpatient UtilizationGeneral Hospital/Acute Care: Total (ipua) | | | R | Reportable |
| Inpatient UtilizationGeneral Hospital/Acute Care: Dual Eligibles (ipub) | | | NR | Not Reported |
| Inpatient UtilizationGeneral Hospital/Acute Care: Disabled (ipuc) | | | NR | Not Reported |
| Inpatient UtilizationGeneral Hospital/Acute Care: Other (ipud) | | | NR | Not Reported |
| Identification of Alcohol and Other Drug Services: Total (iada) | Y | | R | Reportable |
| Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb) | Ν | | NQ | Not Required |
| Identification of Alcohol and Other Drug Services: Disabled (iadc) | Ν | | NQ | Not Required |
| Identification of Alcohol and Other Drug Services: Other (iadd) | Ν | | NQ | Not Required |
| Mental Health Utilization: Total (mpta) | Y | | R | Reportable |
| Mental Health Utilization: Dual Eligibles (mptb) | Ν | | NQ | Not Required |
| Mental Health Utilization: Disabled (mptc) | Ν | | NQ | Not Required |
| Mental Health Utilization: Other (mptd) | Ν | | NQ | Not Required |
| Antibiotic Utilization: Total (abxa) | Y | | R | Reportable |

| Antibiotic Utilization: Dual Eligibles (abxb) | N | NQ | Not Required |
|--|---|----|--------------|
| Antibiotic Utilization: Disabled (abxc) | N | NQ | Not Required |
| Antibiotic Utilization: Other (abxd) | N | NQ | Not Required |
| Standardized Healthcare-Associated Infection Ratio (hai) | | R | Reportable |
| Health Plan Descriptive | | | |
| Board Certification (bcr) | | UN | Unaudited |
| Enrollment by Product Line: Total (enpa) | | R | Reportable |
| Enrollment by Product Line: Dual Eligibles (enpb) | | NR | Not Reported |
| Enrollment by Product Line: Disabled (enpc) | | NR | Not Reported |
| Enrollment by Product Line: Other (enpd) | | NR | Not Reported |
| Enrollment by State (ebs) | | R | Reportable |
| Language Diversity of Membership (Idm) | | NR | Not Reported |
| Race/Ethnicity Diversity of Membership (rdm) | | NR | Not Reported |
| Total Membership (tlm) | | R | Reportable |
| Measures Collected using Electronic | | | |
| Utilization of the PHQ-9 to Monitor Depression | | | |
| Symptoms | | | |
| for Adolescents and Adults (dms) | | | |
| Inclusion in ECDS: Total | | NR | Not Reported |
| Utilization of PHQ-9: Total | | NR | Not Reported |
| Depression and Remission or Response for Adolescents | | | |
| and Adults (drr) | | | |
| EDCS Coverage: Total | | NR | Not Reported |
| Follow-up PHQ-9: Total | | NR | Not Reported |
| Depression Remission: Total | | NR | Not Reported |
| Depression Response: Total | | NR | Not Reported |